Loading...
MDVL logo

MedAvail Holdings, Inc.NasdaqCM:MDVL Stok Raporu

Piyasa Değeri US$2.9m
Hisse Fiyatı
US$0.0001
Adil Değerim
Kullanılamıyor
1Y-90.3%
7D-40.6%
1D
Portföy Değeri
​
Görünüm

MedAvail Holdings, Inc.

NasdaqCM:MDVL Stok Raporu

Piyasa değeri: US$2.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MedAvail Holdings (MDVL) Hisse Özeti

MedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, and kiosk solutions in the United States and Canada. Daha fazla detay

Risk Analizi

Kazançlar son 5 yılda yılda 25.1% oranında azaldı

Anlamlı bir piyasa değeri yok ( $3M )

Son 3 ayda hisse senedi fiyatı US piyasasına kıyasla oldukça dalgalı

1 yıldan az nakit akışı var


MDVL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

MedAvail Holdings, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti MedAvail Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$1.80
52 Haftanın En Yüksek SeviyesiUS$21.26
52 Haftanın En Düşük SeviyesiUS$1.31
Beta-0.13
1 Aylık Değişim-53.55%
3 Aylık Değişim-53.24%
1 Yıllık Değişim-90.35%
3 Yıllık Değişim-99.72%
5 Yıllık Değişimn/a
Halka arzdan bu yana değişim-99.60%

Son Haberler & Güncellemeler

Recent updates

Analiz Makalesi • Aug 17

Slammed 31% MedAvail Holdings, Inc. (NASDAQ:MDVL) Screens Well Here But There Might Be A Catch

MedAvail Holdings, Inc. ( NASDAQ:MDVL ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Aug 02

MedAvail Holdings: More Stock Dilution Seems Inevitable And I'm Bearish

MedAvail is a prescription drug-dispensing kiosks startup whose revenues are growing by over 100% year-on-year at the moment. However, the gross margin is barely positive and the operating loss expanded to $12.8 million in Q1 2022. Cash used in operational activities rose to $13.3 million in Q1 2022 and I think that the company will need another capital increase around the end of the year. However, short selling seems dangerous at the moment as the short borrow fee rate is almost 80%. Introduction I like writing about under covered stocks on SA, and today I'm taking a look at MedAvail Holdings (MDVL). It's a company focused on pharmacy automation kiosks and the growth of its business looks compelling. However, the operating expenses are high and the company is set to run low on cash again soon. I think that another stock dilution seems inevitable in the near future. Overall, I don't think that the business is worth much in its current state and I'm bearish. Let's review. Overview of the business and financials MedAvail is a pharmacy technology and services company whose main product is a MedCenter. This is a pharmacist controlled, customer-interactive, prescription dispensing system that looks somewhat like an ATM on the outside. MedAvail It's an interesting concept but there are several competitors with a similar business, including Omnicell (NASDAQ: OMCL) Dispension Industries, Pharmaself24. What MedAvail is offering doesn't seem to be unique. The company also operates full-service retail pharmacies under the SpotRx brand that use its automated pharmacy technology. MedAvail has bet on a hub and spoke model and it currently has operations in the states of Arizona, California, Michigan, and Florida. It plans to set foot in Texas and Illinois in the near future. MedAvail has partnered with several large brands, including IMA Medical Group, CareMore Health, Cigna (NYSE: CI), and Cano Health. MedAvail The dispensing units usually ramp up to $1 million in annual revenues by their second year. As of December 2021, MedAvail had a total of 13 dispensing units that were operating for over 18 months, and it plans to set up about 25-30 dispensing units in 2022. For the graphs below, note that net cumulative deployments exclude decommissioned clinics, pilot and demo sites. MedAvail MedAvail In Q1 2022, retail pharmacy and hardware revenues increased by 126.3% year-on-year thanks to a $5.4 million increase from volume growth in prescription revenue at existing sites as well as new sites in Florida and Michigan. Unfortunately, there don't appear to be significant economies of scale as the total cost of products sold and services soared by 132.3% to $8.61 million. In addition, operating expenses rose by 33.1% which led to a widening of the operating loss of MedAvail to $12.8 million in Q1 2022. MedAvail Looking at the future, the targeted milestones listed in MedAvail's latest corporate presentation include increasing the network of dispensing MedCenters to more than 100 in existing markets. I don't think this should be hard to achieve considering there were already 88 dispensing units in operation as of March 2022, up from 68 units in December 2021. The company also aims to reduce its quarterly cash burn by 20% by improving its gross margin and achieving greater hub pharmacy utilization. It also highlighted a procurement strategy for sourcing pharmaceuticals at optimal cost to drive utilization and the appropriate mix of medications. However, I don't see a path to profitability anytime soon considering the gross margin hasn't seen much improvement over the past few quarters and that the operating loss has increased by over 37% in just a year. In my view, this is a major issue as it has led to an increase of net cash used in operating activities to $13.3 million in Q1 2022, compared to $9.8 million a year earlier. As a result, MedAvail closed March with cash and cash equivalents of only $5.27 million. The company then raised $40 million through the issuance of 37.6 million shares at $1.0625 apiece in April 2022. Yet, I think that another large private placement is likely to take place around the end of 2022 due to the increase of cash used in operating activities. I think that more stock dilution seems inevitable at the moment. Turning our attention to the balance sheet, we can see that MedAvail has an asset-light business model and cash, receivables, and inventories accounted for almost half of the $27.7 million in total assets at the end of Q1 2022. I find it concerning that the accumulated deficit has surpassed $200 million. MedAvail Overall, I expect MedAvail to continue growing its revenues at a rapid pace and I think the annual run rate could surpass $50 million by the end of 2022. However, the gross margin is barely positive and when you add operating expenses, the picture isn't pretty. And with net cash used in operations growing rapidly, I think that another large capital increase is likely in a few months. I'm bearish but I don't think that this is a good time to be short selling MedAvail. According to data from Fintel, there are 250,000 shares available for borrowing as of the time of writing but the short borrow fee rate is 79.39%. And if you want to rely on put options instead, the lowest available strike price at the moment is $2.50.
Analiz Makalesi • Aug 17

Some Analysts Just Cut Their MedAvail Holdings, Inc (NASDAQ:MDVL) Estimates

The latest analyst coverage could presage a bad day for MedAvail Holdings, Inc ( NASDAQ:MDVL ), with the analysts...
Analiz Makalesi • May 24

Calculating The Intrinsic Value Of MedAvail Holdings, Inc (NASDAQ:MDVL)

Does the May share price for MedAvail Holdings, Inc ( NASDAQ:MDVL ) reflect what it's really worth? Today, we will...
Analiz Makalesi • Feb 20

Is There An Opportunity With MedAvail Holdings, Inc's (NASDAQ:MDVL) 32% Undervaluation?

In this article we are going to estimate the intrinsic value of MedAvail Holdings, Inc ( NASDAQ:MDVL ) by taking the...

Hissedar Getirileri

MDVLUS Consumer RetailingUS Pazar
7D-40.6%-5.2%1.0%
1Y-90.3%14.6%28.7%

Getiri vs. Endüstri: MDVL geçen yıl % 14.6 oranında getiri sağlayan US Consumer Retailing sektörünün gerisinde kaldı.

Getiri vs Piyasa: MDVL geçen yıl % 28.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is MDVL's price volatile compared to industry and market?
MDVL volatility
MDVL Average Weekly Movement30.0%
Consumer Retailing Industry Average Movement5.2%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

İstikrarlı Hisse Senedi Fiyatı: MDVL hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: MDVL 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 21% dan 30% a yükseldi.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
2015279Mark Doerrmedavail.com

MedAvail Holdings, Inc. Temel Bilgiler Özeti

MedAvail Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MDVL temel i̇stati̇sti̇kler
Piyasa değeriUS$2.91m
Kazançlar(TTM)-US$54.34m
Gelir(TTM)US$43.33m
0.1x
P/S Oranı
-0.1x
F/K Oranı

MDVL aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MDVL gelir tablosu (TTM)
GelirUS$43.33m
Gelir MaliyetiUS$41.08m
Brüt KârUS$2.25m
Diğer GiderlerUS$56.59m
Kazançlar-US$54.34m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-33.67
Brüt Marj5.18%
Net Kâr Marjı-125.43%
Borç/Özkaynak Oranı6.5%

MDVL uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2024/02/03 14:47
Gün Sonu Hisse Fiyatı2024/02/02 00:00
Kazançlar2023/06/30
Yıllık Kazançlar2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

MedAvail Holdings, Inc. 2 Bu analistlerden , raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Brooks O'NeilLake Street Capital Markets, LLC
Charles RhyeeTD Cowen